#SFHS2608870AOrder of April 8, 2026, on the Reimbursement Conditions for Certain Pharmaceutical Specialties
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The law mandates that a specific HIV treatment, Raltegravir BGA 600 mg, is now covered by health insurance in France for adults and children over 40 kg. It affects pharmaceutical companies and patients by reducing costs for this treatment when used with other antiretrovirals.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Raltegravir BGA 600 mg is now covered by health insurance for HIV treatment.
- Coverage is applicable for adults and children over 40 kg.
- Affects pharmaceutical companies and patients by reducing treatment costs.
Obligations
What this law requires
Ensure Raltegravir BGA 600 mg (UCD code 34008 900 428 8 8) manufactured by Biogaran is covered by health insurance reimbursement in France
Only reimburse Raltegravir BGA 600 mg when used in combination with other antiretroviral medications for HIV-1 treatment
Only provide reimbursement coverage for Raltegravir BGA 600 mg in patients who are adults or children weighing at least 40 kg
Eliminate patient cost-sharing (participation de l'assuré) for Raltegravir BGA 600 mg when prescribed under covered indications
Publish this order in the Journal officiel de la République française